Bolt Biotherapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BOLT | HBP.TO | BCTX | IMMP | ATORX.ST | NXTC | |
|---|---|---|---|---|---|---|
| Market cap | 15.42M | 70.27M | 27.86M | 21.74M | 38.54M | 26.78M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.3 | -8.4 | -8.2 | -0.9 | -0.1 | -1.0 |
| Price/book | 1.0 | 4.8 | 1.7 | 0.5 | 0.3 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +36.82% | −54.68% | −67.55% | −91.06% | −99.44% | −38.63% |
| Today | −0.46% | 0.00% | +5.98% | −1.50% | +0.93% | −1.02% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BOLT news ›Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications
Prana’s second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. First-in-human studies in healthy volunteers and patients are expected to begin in the second half of 2027, with clinical…
Bolt Biotherapeutics, Inc. (BOLT) M&A Call Prepared Remarks Transcript
Bolt Biotherapeutics, Inc. (BOLT) M&A Call October 26, 2026 8:30 AM EDT William Quinn - CEO, CFO, President, Secretary & DirectorSheila Gujrathi - Chief Strategy Officer & DirectorRyan SullivanHector Ortega Good morning, and welcome to the…
Biotech Stock Bolt Biotherapeutics (Nasdaq: BOLT) Soars on Acquisition News
Bolt Biotherapeutics trades up more than 63% to a 52-week high after a sign-and-close reverse merger with Prana and a $120 million private placement. Bolt makes the Nasdaq top gainer list today following acquisition news. The stock is…
Alert wrongly tagged to Bolt Biotherapeutics withdrawn
An alert on Estonian ride-hailing platform Bolt collaborating with Nvidia was inadvertently tagged to Bolt Biotherapeutics, an unrelated entity, and has been withdrawn. For Reuters coverage on Bolt's... Biotechnology & Medical Research…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- investorideas.com1
- investors.boltbio.com1
- marketscreener.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.